ClinicalTrials.gg
CompletedNCT01336972Updated Mar 5, 2019Results posted

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Phase 2 interventional study of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-03-05.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
12th of 18
29 · median 91
Started
2010
with 3 others
Phase 2
7 of 18
none open now
Registered
8th of 18
by date
Lead sponsor
9 of 18
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 12th largest by enrollment, is one of 4 that started in 2010, is one of 7 in phase 2, and was the 8th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

The purpose of the trial was to determine the short-term effects of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) at various levels of renal function.

Read the detailed description

Renal function was assessed during screening with the estimated glomerular filtration rate (eGFR), which was calculated with the 4-variable modification of diet in renal disease (MDRD) equation using a minimum of 2 creatinine measurements. The eGFR values were used to categorize participants into 1 of 3 mutually exclusive strata (> 60 [Group A], 30 to 60 [Group B], and \< 30 [Group C] mL/min/1.73 m\^2). Each of the 3 groups received the same tolvaptan treatment.

During the 3-week treatment period, participants were up-titrated on a weekly basis from 45/15 mg to 60/30 mg to 90/30 mg (AM and PM [8 hours later] split-dose) to the maximally tolerated dose. The 3-week treatment period was followed by a 3-week post-treatment period during which no study medication was administered.

The effects of the highest tolerated split-dose of tolvaptan on renal hemodynamics and pharmacokinetic and pharmacodynamic parameters were assessed throughout the 6 weeks of the study. The reversibility of changes during the post-treatment period after withdrawal of the drug was determined and the acute transitory effects on kidney volume were also explored.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of autosomal dominant polycystic kidney disease (ADPKD) by Ravine criteria.

Exclusion criteria

Exclusion Criteria:

  • Renal replacement therapy.
  • Use of therapies for the purpose of affecting polycystic kidney disease (PKD) cysts.
  • Evidence of significant renal disease, eg, active glomerular nephritides, renal cancer, single kidney.
  • Significant risk-factors for renal impairment, eg, chronic use of diuretics, advanced diabetes, use of nephrotoxic drugs.
  • History of significant coagulation defects or hemorrhagic diathesis.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Group A - eGFR > 60 ml/min/1.73m^2

    Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM \[8 hours later\]) to the maximally tolerated dose.

    Drug: Tolvaptan

  • Experimental
    Group B - eGFR 30 to 60 ml/min/1.73m^2

    Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM \[8 hours later\]) to the maximally tolerated dose.

    Drug: Tolvaptan

  • Experimental
    Group C - eGFR < 30 ml/min/1.73m^2

    Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM \[8 hours later\]) to the maximally tolerated dose.

    Drug: Tolvaptan

Interventions

  • Tolvaptan was supplied as 15 and 30 mg tablets.

    Also known as: OPC-41061

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.

    Renal function measurements were performed using the constant infusion method with 125I-iothalamate and 131I-hippuran. A priming solution containing 20 mL infusion solution (0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippuran) was given at 08:00 hours, followed by a constant infusion of 6 to 12 mL/h, with the lowest infusion rates in subjects with impaired renal function, based on previously known serum creatinine concentrations. Plasma concentrations of both tracers were allowed to stabilize during a 1.5-hour equilibration, which was followed by two 2-hour periods (09:30 to 11:30 hours and 11:30 to 13:30 hours) for simultaneous clearances of 125I-iothalamate and 131I-hippuran. Blood was drawn at 1, 2, 3, 4, and 5 hours post consumption of water/tolvaptan (08:30 hours). The mGFR was corrected for voiding errors.

    Time frame: After 3 weeks of treatment and 3 weeks post treatment

  2. Mean Change From Baseline in Effective Renal Plasma Flow (ERPF) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.

    Renal function measurements were performed using the constant infusion method with 125I-iothalamate and 131I-hippuran. A priming solution containing 20 mL infusion solution (0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippuran) was given at 08:00 hours, followed by a constant infusion of 6 to 12 mL/h, with the lowest infusion rates in subjects with impaired renal function, based on previously known serum creatinine concentrations. Plasma concentrations of both tracers were allowed to stabilize during a 1.5-hour equilibration, which was followed by two 2-hour periods (09:30 to 11:30 hours and 11:30 to 13:30 hours) for simultaneous clearances of 125I-iothalamate and 131I-hippuran. Blood was drawn at 1, 2, 3, 4, and 5 hours post consumption of water/tolvaptan (08:30 hours).

    Time frame: After 3 weeks of treatment and 3 weeks post treatment

  3. Mean Change From Baseline in Filtration Fraction (GFR/ERFP) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.

    Renal function measurements were performed using the constant infusion method with 125I-iothalamate and 131I-hippuran. A priming solution containing 20 mL infusion solution (0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippuran) was given at 08:00 hours, followed by a constant infusion of 6 to 12 mL/h, with the lowest infusion rates in subjects with impaired renal function, based on previously known serum creatinine concentrations. Plasma concentrations of both tracers were allowed to stabilize during a 1.5-hour equilibration, which was followed by two 2-hour periods (09:30 to 11:30 hours and 11:30 to 13:30 hours) for simultaneous clearances of 125I-iothalamate and 131I-hippuran. Blood was drawn at 1, 2, 3, 4, and 5 hours post consumption of water/tolvaptan (08:30 hours).

    Time frame: After 3 weeks of treatment and 3 weeks post treatment

Secondary outcomes

  1. Mean Change From Baseline in Free Water Clearance After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment

    Renal function measurements were performed using the constant infusion method with 125I-iothalamate and 131I-hippuran. A priming solution containing 20 mL infusion solution (0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippuran) was given at 08:00 hours, followed by a constant infusion of 6 to 12 mL/h, with the lowest infusion rates in subjects with impaired renal function, based on previously known serum creatinine concentrations. Plasma concentrations of both tracers were allowed to stabilize during a 1.5-hour equilibration, which was followed by two 2-hour periods (09:30 to 11:30 hours and 11:30 to 13:30 hours) for simultaneous clearances of 125I-iothalamate and 131I-hippuran. Blood was drawn at 1, 2, 3, 4, and 5 hours post consumption of water/tolvaptan (08:30 hours).

    Time frame: After 3 weeks of treatment and 3 weeks post treatment

  2. Time to Peak Plasma Concentration (Cmax) After 3 Weeks of Tolvaptan Treatment.

    Blood sampling for determination of tolvaptan concentrations took place at the Baseline, Final Treatment, and the Post Treatment or Early Termination visits. At the Final Treatment visit (Day 21 \[+/- 1 day)\]), blood samples were collected prior to the start of infusion of study treatment and at 1, 2, 3, 4, and 5 hours postdose. At the Baseline (Day 0), and Post Treatment visit (3 weeks \[+/-3 days\] after last dose), a blood sample was collected prior to the start of infusion of study treatment.

    Time frame: Day 0: 0 hour, Day 21: (0, 1, 2, 3, 4 and 5 hours postdose), 3 Weeks after last dose: 0 hour

  3. Time to Peak Plasma Concentration (Tmax) After 3 Weeks of Tolvaptan Treatment.

    Blood sampling for determination of tolvaptan concentrations took place at the Baseline, Final Treatment, and the Post Treatment or Early Termination visits. At the Final Treatment visit (Day 21 \[+/- 1 day)\]), blood samples were collected prior to the start of infusion of study treatment and at 1, 2, 3, 4, and 5 hours postdose. At the Baseline (Day 0), and Post Treatment visit (3 weeks \[+/-3 days\] after last dose), a blood sample was collected prior to the start of infusion of study treatment.

    Time frame: Day 0: 0 hour, Day 21: (0, 1, 2, 3, 4 and 5 hours postdose), 3 Weeks after last dose: 0 hour

  4. Area Under the Concentration-time Curve From 0 to 5 Hours (AUC0-5) After 3 Weeks of Tolvaptan Treatment.

    Blood sampling for determination of tolvaptan concentrations took place at the Baseline, Final Treatment, and the Post Treatment or Early Termination visits. At the Final Treatment visit (Day 21 \[+/- 1 day)\]), blood samples were collected prior to the start of infusion of study treatment and at 1, 2, 3, 4, and 5 hours postdose. At the Baseline (Day 0), and Post Treatment visit (3 weeks \[+/-3 days\] after last dose), a blood sample was collected prior to the start of infusion of study treatment.

    Time frame: Day 0: 0 hour, Day 21: (0, 1, 2, 3, 4 and 5 hours postdose), 3 Weeks after last dose: 0 hour

  5. Percentage Change From Baseline in Total Kidney Volume (TKV) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.

    TKV was measured using magnetic resonance imaging.

    Time frame: After 3 weeks of treatment and 3 weeks post treatment

  6. Mean Change From Baseline in 24 Hour Urine Volume After 3 Weeks Tolvaptan Treatment and at 3 Weeks Post Treatment.

    A 24-hour split urine sample (approximate times: 0700 to 1700 hours, 1700 hours to bedtime, and bedtime to 0700 hours) was collected beginning the day before the Baseline, Final Treatment, and Post Treatment visits and ending at admission to the renal function ward. Individual voids in a collection interval were pooled and the total volume determined.

    Time frame: 24 hours

  7. Mean Change From Baseline in 2 Hour Urine Volume After 3 Weeks Tolvaptan Treatment and at 3 Weeks Post Treatment.

    The volume of urine from each 2-hour urine collection in the renal function tests at Baseline, Final Treatment, and Post Treatment was recorded. Individual voids in a collection interval were pooled before determination of total volume.

    Time frame: 2 hours

07

Results

Posted Jun 28, 2017

Participant flow

The trial was conducted in 29 participants at one center in The Netherlands. Participants were stratified based on their estimated glomerular filtration rate (eGFR): \>60, 30-60 and \<30 millilitres (mL)/minute (min)/1.73 meter squared (m2). eGFR was assessed using the 4-variable modification of diet in renal disease (MDRD).

Participant flow — Overall Study
MilestoneeGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 ml/Min/1.73m2
Started10109
Completed999
Not completed110
Withdrew: Adverse event110

Outcome measures

PrimaryMean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.

Renal function measurements were performed using the constant infusion method with 125I-iothalamate and 131I-hippuran. A priming solution containing 20 mL infusion solution (0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippuran) was given at 08:00 hours, followed by a constant infusion of 6 to 12 mL/h, with the lowest infusion rates in subjects with impaired renal function, based on previously known serum creatinine concentrations. Plasma concentrations of both tracers were allowed to stabilize during a 1.5-hour equilibration, which was followed by two 2-hour periods (09:30 to 11:30 hours and 11:30 to 13:30 hours) for simultaneous clearances of 125I-iothalamate and 131I-hippuran. Blood was drawn at 1, 2, 3, 4, and 5 hours post consumption of water/tolvaptan (08:30 hours). The mGFR was corrected for voiding errors.

Time frame:
After 3 weeks of treatment and 3 weeks post treatment
Reported as:
Mean · mL/min
Mean Change From Baseline in Measured Glomerular Filtration Rate (mGFR) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.
mL/mineGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Final treatment change from Baseline-8.0 ± 9.1-6.2 ± 6.2-0.7 ± 1.5
Post treatment change from Baseline0.1 ± 4.9-1.5 ± 4.0-1.2 ± 3.0
Statistical analysis
  • eGFR > 60 mL/Min/1.73m2 · paired t-test · p = <0.05 (Test to compare Final Treatment versus Baseline)
  • eGFR 30-60 mL/Min/1.73m2 · paited t-test · p = <0.05 (Test to compare Final Treatment versus Baseline)
  • eGFR <30 mL/Min/1.73m2 · paired t-test · p = >0.05 (Test to compare Final Treatment versus Baseline)
  • eGFR > 60 mL/Min/1.73m2 · paired t-test · p = >0.05 (Test to compare Post Treatment versus Baseline)
  • eGFR 30-60 mL/Min/1.73m2 · paired t-test · p = >0.05 (Test to compare Post Treatment versus Baseline)
  • eGFR <30 mL/Min/1.73m2 · paired t-test · p = >0.05 (Test to compare Post Treatment versus Baseline)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = <0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Post Treatment)
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
PrimaryMean Change From Baseline in Effective Renal Plasma Flow (ERPF) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.

Renal function measurements were performed using the constant infusion method with 125I-iothalamate and 131I-hippuran. A priming solution containing 20 mL infusion solution (0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippuran) was given at 08:00 hours, followed by a constant infusion of 6 to 12 mL/h, with the lowest infusion rates in subjects with impaired renal function, based on previously known serum creatinine concentrations. Plasma concentrations of both tracers were allowed to stabilize during a 1.5-hour equilibration, which was followed by two 2-hour periods (09:30 to 11:30 hours and 11:30 to 13:30 hours) for simultaneous clearances of 125I-iothalamate and 131I-hippuran. Blood was drawn at 1, 2, 3, 4, and 5 hours post consumption of water/tolvaptan (08:30 hours).

Time frame:
After 3 weeks of treatment and 3 weeks post treatment
Reported as:
Mean · mL/min
Mean Change From Baseline in Effective Renal Plasma Flow (ERPF) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.
mL/mineGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Final treatment change from Baseline-16.9 ± 36.4-11.1 ± 18.4-1.7 ± 5.1
Post treatment change from Baseline4.3 ± 30.2-8.4 ± 17.7-1.3 ± 10.3
Statistical analysis
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · paired t-test · p = >0.05 (Test to compare Final Treatment versus Baseline for all treatment groups)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · paired t-test · p = >0.05 (Test to compare Post Treatment versus Baseline for all treatment groups)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Post Treatment)
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Post Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Post Treatment)
PrimaryMean Change From Baseline in Filtration Fraction (GFR/ERFP) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.

Renal function measurements were performed using the constant infusion method with 125I-iothalamate and 131I-hippuran. A priming solution containing 20 mL infusion solution (0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippuran) was given at 08:00 hours, followed by a constant infusion of 6 to 12 mL/h, with the lowest infusion rates in subjects with impaired renal function, based on previously known serum creatinine concentrations. Plasma concentrations of both tracers were allowed to stabilize during a 1.5-hour equilibration, which was followed by two 2-hour periods (09:30 to 11:30 hours and 11:30 to 13:30 hours) for simultaneous clearances of 125I-iothalamate and 131I-hippuran. Blood was drawn at 1, 2, 3, 4, and 5 hours post consumption of water/tolvaptan (08:30 hours).

Time frame:
After 3 weeks of treatment and 3 weeks post treatment
Reported as:
Mean · Ratios
Mean Change From Baseline in Filtration Fraction (GFR/ERFP) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.
RatioseGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Final treatment change from Baseline-0.005 ± 0.017-0.013 ± 0.016-0.010 ± 0.014
Post treatment change from Baseline-0.003 ± 0.0180.005 ± 0.015-0.016 ± 0.023
Statistical analysis
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · paired t-test · p = >0.05 (Test to compare Final Treatment versus Baseline)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · paired t-test · p = >0.05 (Test to compare Post Treatment versus Baseline for all treatment groups)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Post Treatment)
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = <0.05 (Test to compare treatment groups at Post Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Post Treatment)
SecondaryMean Change From Baseline in Free Water Clearance After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment

Renal function measurements were performed using the constant infusion method with 125I-iothalamate and 131I-hippuran. A priming solution containing 20 mL infusion solution (0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippuran) was given at 08:00 hours, followed by a constant infusion of 6 to 12 mL/h, with the lowest infusion rates in subjects with impaired renal function, based on previously known serum creatinine concentrations. Plasma concentrations of both tracers were allowed to stabilize during a 1.5-hour equilibration, which was followed by two 2-hour periods (09:30 to 11:30 hours and 11:30 to 13:30 hours) for simultaneous clearances of 125I-iothalamate and 131I-hippuran. Blood was drawn at 1, 2, 3, 4, and 5 hours post consumption of water/tolvaptan (08:30 hours).

Time frame:
After 3 weeks of treatment and 3 weeks post treatment
Reported as:
Mean · mL/min
Mean Change From Baseline in Free Water Clearance After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment
mL/mineGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Final treatment change from Baseline4.334 ± 3.2682.822 ± 1.7151.701 ± 1.225
Post treatment change from Baseline-0.675 ± 1.475-0.195 ± 1.1240.382 ± 0.543
Statistical analysis
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · paired t-test · p = <0.05
  • eGFR > 60 mL/Min/1.73m2 · paired t-test · p = >0.05
  • eGFR 30-60 mL/Min/1.73m2 · paired t-test · p = >0.05
  • eGFR <30 mL/Min/1.73m2 · paired t-test · p = <0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05Test to compare treatment groups at Final Treatment
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · paired t-test · p = >0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Final Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Post Treatment)
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05 (Test to compare treatment groups at Post Treatment)
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = <0.05 (Test to compare treatment groups at Post Treatment)
SecondaryTime to Peak Plasma Concentration (Cmax) After 3 Weeks of Tolvaptan Treatment.

Blood sampling for determination of tolvaptan concentrations took place at the Baseline, Final Treatment, and the Post Treatment or Early Termination visits. At the Final Treatment visit (Day 21 \[+/- 1 day)\]), blood samples were collected prior to the start of infusion of study treatment and at 1, 2, 3, 4, and 5 hours postdose. At the Baseline (Day 0), and Post Treatment visit (3 weeks \[+/-3 days\] after last dose), a blood sample was collected prior to the start of infusion of study treatment.

Time frame:
Day 0: 0 hour, Day 21: (0, 1, 2, 3, 4 and 5 hours postdose), 3 Weeks after last dose: 0 hour
Reported as:
Mean · ng/mL
Time to Peak Plasma Concentration (Cmax) After 3 Weeks of Tolvaptan Treatment.
ng/mLeGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Time to Peak Plasma Concentration (Cmax) After 3 Weeks of Tolvaptan Treatment.828 ± 297591 ± 235840 ± 355
SecondaryTime to Peak Plasma Concentration (Tmax) After 3 Weeks of Tolvaptan Treatment.

Blood sampling for determination of tolvaptan concentrations took place at the Baseline, Final Treatment, and the Post Treatment or Early Termination visits. At the Final Treatment visit (Day 21 \[+/- 1 day)\]), blood samples were collected prior to the start of infusion of study treatment and at 1, 2, 3, 4, and 5 hours postdose. At the Baseline (Day 0), and Post Treatment visit (3 weeks \[+/-3 days\] after last dose), a blood sample was collected prior to the start of infusion of study treatment.

Time frame:
Day 0: 0 hour, Day 21: (0, 1, 2, 3, 4 and 5 hours postdose), 3 Weeks after last dose: 0 hour
Reported as:
Median · hours
Time to Peak Plasma Concentration (Tmax) After 3 Weeks of Tolvaptan Treatment.
hourseGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Time to Peak Plasma Concentration (Tmax) After 3 Weeks of Tolvaptan Treatment.2.0 (1.00 to 3.00)2.0 (1.00 to 3.00)2.0 (1.00 to 5.00)
SecondaryArea Under the Concentration-time Curve From 0 to 5 Hours (AUC0-5) After 3 Weeks of Tolvaptan Treatment.

Blood sampling for determination of tolvaptan concentrations took place at the Baseline, Final Treatment, and the Post Treatment or Early Termination visits. At the Final Treatment visit (Day 21 \[+/- 1 day)\]), blood samples were collected prior to the start of infusion of study treatment and at 1, 2, 3, 4, and 5 hours postdose. At the Baseline (Day 0), and Post Treatment visit (3 weeks \[+/-3 days\] after last dose), a blood sample was collected prior to the start of infusion of study treatment.

Time frame:
Day 0: 0 hour, Day 21: (0, 1, 2, 3, 4 and 5 hours postdose), 3 Weeks after last dose: 0 hour
Reported as:
Mean · ng.h/mL
Area Under the Concentration-time Curve From 0 to 5 Hours (AUC0-5) After 3 Weeks of Tolvaptan Treatment.
ng.h/mLeGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Area Under the Concentration-time Curve From 0 to 5 Hours (AUC0-5) After 3 Weeks of Tolvaptan Treatment.2850 ± 7742140 ± 8633100 ± 1060
SecondaryPercentage Change From Baseline in Total Kidney Volume (TKV) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.

TKV was measured using magnetic resonance imaging.

Time frame:
After 3 weeks of treatment and 3 weeks post treatment
Reported as:
Mean · Percent
Percentage Change From Baseline in Total Kidney Volume (TKV) After 3 Weeks of Tolvaptan Treatment and at 3 Weeks Post Treatment.
PercenteGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Final treatment change from Baseline-4.5 ± 3.7-4.6 ± 2.7-1.9 ± 1.9
Post treatment change from Baseline-1.5 ± 2.3-2.4 ± 3.8-0.7 ± 2.5
Statistical analysis
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · paired t-test · p = <0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · paired t-test · p = <0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = <0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
SecondaryMean Change From Baseline in 24 Hour Urine Volume After 3 Weeks Tolvaptan Treatment and at 3 Weeks Post Treatment.

A 24-hour split urine sample (approximate times: 0700 to 1700 hours, 1700 hours to bedtime, and bedtime to 0700 hours) was collected beginning the day before the Baseline, Final Treatment, and Post Treatment visits and ending at admission to the renal function ward. Individual voids in a collection interval were pooled and the total volume determined.

Time frame:
24 hours
Reported as:
Mean · mL
Mean Change From Baseline in 24 Hour Urine Volume After 3 Weeks Tolvaptan Treatment and at 3 Weeks Post Treatment.
mLeGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Final treatment change from Baseline4551.1 ± 1792.73274.4 ± 1293.32215.0 ± 1142.0
Post treatment change from Baseline-312.2 ± 468.2-287.2 ± 744.7143.1 ± 390.4
Statistical analysis
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Paired t-test · p = <0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = <0.05
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = <0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Paired t-test · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = <0.05
SecondaryMean Change From Baseline in 2 Hour Urine Volume After 3 Weeks Tolvaptan Treatment and at 3 Weeks Post Treatment.

The volume of urine from each 2-hour urine collection in the renal function tests at Baseline, Final Treatment, and Post Treatment was recorded. Individual voids in a collection interval were pooled before determination of total volume.

Time frame:
2 hours
Reported as:
Mean · mL
Mean Change From Baseline in 2 Hour Urine Volume After 3 Weeks Tolvaptan Treatment and at 3 Weeks Post Treatment.
mLeGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Final treatment change from Baseline888.9 ± 730.3625.6 ± 478.5356.7 ± 283.2
Post treatment change from Baseline-187.8 ± 218.2-10.0 ± 335.127.5 ± 155.0
Statistical analysis
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · paired te-test · p = <0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 · paired t-test · p = <0.05
  • eGFR 30-60 mL/Min/1.73m2 · paired t-test · p = >0.05
  • eGFR <30 mL/Min/1.73m2 · Paired t-test · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR 30-60 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR 30-60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05
  • eGFR > 60 mL/Min/1.73m2 vs eGFR <30 mL/Min/1.73m2 · Wilcoxon (Mann-Whitney) · p = >0.05

Adverse events

Collected over Adverse events were collected from the time of signing the informed consent to 7 days after the early termination visit or up to the 21 Day Post-Treatment Visit. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
eGFR > 60 mL/Min/1.73m2—1/10 (10%)10/10 (100%)
eGFR 30-60 mL/Min/1.73m2—0/10 (0%)10/10 (100%)
eGFR <30 mL/Min/1.73m2—1/9 (11.1%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventeGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
Angina pectorisCardiac disorders0/100/101/9
PolyuriaRenal and urinary disorders1/100/100/9
Most frequent other events
Showing 10 of 50
Most frequent other events
EventeGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2
ThirstGeneral disorders10/1010/108/9
PolyuriaRenal and urinary disorders9/109/107/9
NocturiaRenal and urinary disorders8/106/106/9
Dry mouthGastrointestinal disorders6/105/105/9
FatigueGeneral disorders2/101/103/9
Decreased appetiteMetabolism and nutrition disorders2/103/102/9
Renal painRenal and urinary disorders3/100/101/9
NauseaGastrointestinal disorders1/101/102/9
OedemaGeneral disorders0/100/102/9
HeadacheNervous system disorders2/102/102/9

Baseline characteristics

Age, Continuous
Age, Continuous(Years)eGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2Total
Mean38.7 ± 7.147.8 ± 12.952.1 ± 6.746.0 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)eGFR > 60 mL/Min/1.73m2eGFR 30-60 mL/Min/1.73m2eGFR <30 mL/Min/1.73m2Total
Female66214
Male44715
08

Study locations

1 site
  • University Medical Center Groningen
    Groningen, 9713 GZ, Netherlands
09

References and documents

Publications

  • Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int. 2013 Dec;84(6):1278-86. doi: 10.1038/ki.2013.285. Epub 2013 Jul 31. PubMed 23903369 ↗
  • Reddy B, Chapman AB. Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy? Am J Kidney Dis. 2015 Jun;65(6):811-3. doi: 10.1053/j.ajkd.2015.03.004. No abstract available. PubMed 26003607 ↗
  • Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15. PubMed 25600953 ↗
  • Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan. Am J Kidney Dis. 2019 Mar;73(3):354-362. doi: 10.1053/j.ajkd.2018.09.016. Epub 2018 Dec 19. PubMed 30578153 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 5 years 7 months after primary completion. A results delay was requested in Dec 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2011
First posted
Apr 18, 2011
Start
Oct 2010
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results delay requested
Dec 3, 2012
Results first posted
Jun 28, 2017
Last update
Mar 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01336972
Responsible party
Sponsor
First posted
Apr 18, 2011
Start date
Oct 2010
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Jun 28, 2017
Last update
Mar 5, 2019

Study contacts

Frank Czerwiec, MD, PhD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.
Ron T Gansevoort, MD
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion